Category Archives: Hepatic Cell

Hepatic Cell News is an online publication and email newsletter covering the top research on hepatocytes and liver diseases.
Subscribe
The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. The newsletter covers areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!

BLOC1S1/GCN5L1/BORCS1 Is a Critical Mediator for the Initiation of Autolysosomal Tubulation

The genetic reintroduction of BLOC1S1 rescued lysosomal tubulation in liver-specific knockout hepatocytes, but not when KIF5B was concurrently depleted.
[Autophagy]
Wu, K., Seylani, A., Wu, J., Wu, X., Bleck, C. K. E., & Sack, M. N. (2021). BLOC1S1/GCN5L1/BORCS1 is a critical mediator for the initiation of autolysosomal tubulation. Autophagy, 0(ja), null. https://doi.org/10.1080/15548627.2021.1894759 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Targeting EphA2 Suppresses Hepatocellular Carcinoma Initiation and Progression by Dual Inhibition of JAK1/STAT3 and AKT Signaling

The authors discovered that targeting EphA2 suppressed both AKT and JAK1/STAT3 signaling, two separate oncogenic pathways in hepatocelllar carcinoma.
[Cell Reports]
Wang, H., Hou, W., Perera, A., Bettler, C., Beach, J. R., Ding, X., Li, J., Denning, M. F., Dhanarajan, A., Cotler, S. J., Joyce, C., Yin, J., Ahmed, F., Roberts, L. R., & Qiu, W. (2021). Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Reports, 34(8). https://doi.org/10.1016/j.celrep.2021.108765 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Gene Editing and Synthetically Accessible Inhibitors Reveal Role for TPC2 in HCC Cell Proliferation and Tumor Growth

Investigators report that TPC2 knockout reduced proliferation of cancer cells in vitro, affected their energy metabolism, and successfully abrogated tumor growth in vivo.
[Cell Chemical Biology]
Müller, M., Gerndt, S., Chao, Y.-K., Zisis, T., Nguyen, O. N. P., Gerwien, A., Urban, N., Müller, C., Gegenfurtner, F. A., Geisslinger, F., Ortler, C., Chen, C.-C., Zahler, S., Biel, M., Schaefer, M., Grimm, C., Bracher, F., Vollmar, A. M., & Bartel, K. (2021). Gene editing and synthetically accessible inhibitors reveal role for TPC2 in HCC cell proliferation and tumor growth. Cell Chemical Biology, 0(0). https://doi.org/10.1016/j.chembiol.2021.01.023 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Deubiquitinase USP39 and E3 Ligase TRIM26 Balance the Level of ZEB1 Ubiquitination and Thereby Determine the Progression of Hepatocellular Carcinoma

Scientists revealed that USP39 was highly expressed in human hepatocellular carcinoma (HCC) tissues and correlated with poor prognosis. USP39 depletion inhibited HCC cell proliferation and metastasis by promoting ZEB1 degradation.
[Cell Death & Differentiation]
Li, X., Yuan, J., Song, C., Lei, Y., Xu, J., Zhang, G., Wang, W., & Song, G. (2021). Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma. Cell Death & Differentiation, 1–18. https://doi.org/10.1038/s41418-021-00754-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

SIRT2 Prevents Liver Steatosis and Metabolic Disorders via Deacetylation of HNF4α

Researchers found that SIRT2 was significantly downregulated in livers from advanced NAFLD patients and high‐fat diet (HFD)‐induced non-alcoholic liver disease mice. They revealed that SIRT2 was markedly decreased in obese mice and in palmitate‐treated HepG2 cells.
[Hepatology]
Ren, H., Hu, F., Wang, D., Kang, X., Feng, X., Zhang, L., Zhou, B., Liu, S., & Yuan, G. (n.d.). SIRT2 Prevents Liver Steatosis and Metabolic Disorders via Deacetylation of HNF4α. Hepatology, n/a(n/a). https://doi.org/https://doi.org/10.1002/hep.31773 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis through m6A mRNA Methylation Dependent Mechanism

The authors validated the increased m6A modification and elevated YTHDF1 protein level in sublethal‐heat‐treated hepatocellular carcinoma (HCC) cell lines, HCC patient‐derived xenograft mouse model and patients’ HCC tissues.
[Hepatology]
Su, T., Huang, M., Liao, J., Lin, S., Yu, P., Yang, J., Cai, Y., Zhu, S., Xu, L., Peng, Z., Peng, S., Chen, S., & Kuang, M. (n.d.). Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis through m6A mRNA Methylation Dependent Mechanism. Hepatology, n/a(n/a). https://doi.org/https://doi.org/10.1002/hep.31766 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Proliferation Tracing Reveals Regional Hepatocyte Generation in Liver Homeostasis and Repair

Cell proliferation tracing revealed that, at the whole hepatocyte–population level, more proliferation was detected in a subset of midzonal hepatocytes during liver homeostasis, with less proliferation in periportal hepatocytes and minimal proliferation in pericentral hepatocytes.
[Science]
He, L., Pu, W., Liu, X., Zhang, Z., Han, M., Li, Y., Huang, X., Han, X., Li, Y., Liu, K., Shi, M., Lai, L., Sun, R., Wang, Q.-D., Ji, Y., Tchorz, J. S., & Zhou, B. (2021). Proliferation tracing reveals regional hepatocyte generation in liver homeostasis and repair. Science, 371(6532). https://doi.org/10.1126/science.abc4346 Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Protein Phosphatase PPM1A Dephosphorylates and Activates YAP to Govern Mammalian Intestinal and Liver Regeneration

Genetic ablation or depletion of PPM1A in cells, organoids, and mice elicited an enhanced Yes-associated protein (YAP)/TAZ cytoplasmic retention and resulted in the diminished cell proliferation, severe gut regeneration defects in colitis, and impeded liver regeneration upon injury.
[PLoS Biology]
Zhou, R., Wu, Q., Wang, M., Irani, S., Li, X., Zhang, Q., Meng, F., Liu, S., Zhang, F., Wu, L., Lin, X., Wang, X., Zou, J., Song, H., Qin, J., Liang, T., Feng, X.-H., Zhang, Y. J., & Xu, P. (2021). The protein phosphatase PPM1A dephosphorylates and activates YAP to govern mammalian intestinal and liver regeneration. PLOS Biology, 19(2), e3001122. https://doi.org/10.1371/journal.pbio.3001122 Cite
Full Article
Bookmark

No account yet? Register

0
Share

PIWIL1 Governs the Crosstalk of Cancer Cell Metabolism and Immunosuppressive Microenvironment in Hepatocellular Carcinoma

The authors reported the novel of tumor cell-expressed Piwi Like RNA-Mediated Gene Silencing 1 (PIWIL1) in mediating the crosstalk of fatty acid metabolism and immune response of human hepatocellular carcinoma.
[Signal Transduction and Targeted Therapy]
Wang, N., Tan, H.-Y., Lu, Y., Chan, Y.-T., Wang, D., Guo, W., Xu, Y., Zhang, C., Chen, F., Tang, G., & Feng, Y. (2021). PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 6(1), 1–13. https://doi.org/10.1038/s41392-021-00485-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson

Can-Fite BioPharma Ltd. announced new data from the Phase II advanced liver cancer study including overall survival of nearly 4 years in two patients who are under namodenoson treatment.
[Can-Fite BioPharma Ltd.]
Press Release
Bookmark

No account yet? Register

0
Share

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners, Inc. announced that the Peter Lougheed Center in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.
[Arch Biopartners, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share